Singapore and Ingelheim, January 09, 2020
Enleofen Bio Pte. Ltd. announced today a partnership with Boehringer Ingelheim to develop First-in-Class Anti-IL-11 therapies for a range of fibrotic diseases. Since 2016, YUMAB has been cooperating with Enleofen’s founders to generate novel antibody candidates targeting the interleukin-11 pathway. “Congratulations to Enleofen on the partnership with Boehringer Ingelheim. We are delighted that our close collaboration with the Enleofen team – among other parties – has yielded an extensive range of therapeutic antibody candidates, whose development will now be pushed forward by a leading pharmaceutical company”, says YUMAB CEO Thomas Schirrmann.